C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Official Title: “C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients”

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Arms, Groups and Cohorts in this Clinical Trial

• : Pt with hypercholesteremia
  • Patients treated with CRESTOR because of hypercholesteremia

Primary Measures

• LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
  • Time Frame: 3 visits within 10 weeks
    Safety Issue?: No

Secondary Measures

• Tolerability of CRESTOR-therapy
  • Time Frame: 3 visits within 10 weeks
    Safety Issue?: No

Inclusion Criteria:

• Patients with hypercholesteremia who was never treated with statins before
• Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

• None

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: AstraZeneca Industry

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00688454

Study ID Number: NIS-CCH-CRE-2007/1

ClinicalTrials.gov Identifier: NCT00688454

Health Authority: Switzerland: Ethikkommission